Transfusion of pathogen-reduced platelet components without leukoreduction

Transfusion

Volumn 59, Issue 6, 2019, Pages 1953-1961

  Sim, Joycelyn ^a   Tsoi, Wai Chiu ^b   Lee, Cheuk Kwong ^b   Leung, Rock ^a   Lam, Clarence C K ^a   Koontz, Claudia ^c   Liu, Amy Yingjie ^c   Huang, Norman ^c   Benjamin, Richard J ^c   Vermeij, Hans J ^c   Stassinopoulos, Adonis ^c   Corash, Laurence ^c   Lie, Albert K W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Hong Kong Red Cross Blood Transfusion Service   (Hong Kong)

^c CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE; FUROCOUMARIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GAMMA IRRADIATION; GRAFT RECIPIENT; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LEUKOREDUCTION; MALE; MORTALITY RATE; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; ADVERSE EVENT; ANTISEPSIS; BLOOD; BLOOD TRANSFUSION REACTION; BLOODBORNE BACTERIUM; CASE CONTROL STUDY; CYTOLOGY; DISINFECTION; DRUG EFFECT; GAMMA RADIATION; GRAFT VERSUS HOST REACTION; ISOLATION AND PURIFICATION; LEUKOCYTE; LEUKOCYTE COUNT; MIDDLE AGED; PROCEDURES; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION; VIRUS INACTIVATION;

ADULT; ANTISEPSIS; BLOOD PLATELETS; BLOOD-BORNE PATHOGENS; CASE-CONTROL STUDIES; COHORT STUDIES; DISINFECTION; FEMALE; FUROCOUMARINS; GAMMA RAYS; GRAFT VS HOST DISEASE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; PLATELET TRANSFUSION; TRANSFUSION REACTION; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 85063597312     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15269     Document Type: Article

References (49)

1. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia. N Engl J Med 1997;337:1870-5.
2. Slichter SJ, Kaufman RM, Assman SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-13.
3. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013;368:1771-80.
4. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted patelets and cytomegalovirus seronegative red cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;79:246-50.
5. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
6. Snyder E. Transfusion reactions. In: Hoffman R, Benz E, Shattil S et al., editors. Hematology: Basic Principles and Practice. Philadelphia: Churchill Livingstone; 2000. p. 2300-10.
7. Wu Y, Zou S, Cable R, et al. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010;50:776-86.
8. Ziemann M, Krueger S, Maier AB, et al. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007;47:1972-83.
9. Kopolovic I, Ostro J, Tsubota H, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood 2015;126:406-14.
10. Hong H, Xiao W, Lazarus HM, et al. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2016;127:496-502.
11. Stramer SL, Dodd RY. AAABB transfusion-transmitted diseases emerging infectious diseases subgroup. transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion 2013;53(10 Pt 2):2375-83.
12. Stramer SL, Linnen JM, Carrick JM, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012;52:1657-66.
13. Kuehnert MJ, Epstein JS. Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront. Transfusion 2016;56:1669-72.
14. Osselaer JC, Doyen C, Defoin L, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.
15. Cazenave JP, Isola H, Waller C, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51:622-9.
16. Nussbaumer W, Amato M, Schennach H, et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang 2017;112:249-56.
17. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active hemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:342-52.
18. Corash L, Benjamin RJ. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 2016;56(Suppl 1):S29-38.
19. Cerus Corporation. INTERCEPT Blood System for Platelets. 2014. Concord, CA: Cerus Corporation; 2015.
20. Food and Drug Administration Center for Biologics Evaluation and Research. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components. In: Department of Health and Human Services, editors. Washington (DC): US FDA; 2016.
21. Musso D, Richard V, Broult J, et al. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2014;54:2924-30.
22. US Department of Health and Human Services Food and Drug Administration. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion: draft guidance for industry. In: Center for Biologics Evaluation and Research, editors. Silver Spring (MD): US Department of Health and Human Services Food and Drug Administration; 2016.
23. Jordan CT, Saakadze N, Newman JL, et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 2004;44:1159-65.
24. Fiebig E, Hirschkorn D, Busch M, et al. Loss of inducible CD69 expression on donor T cells (CD3CD69) in platelet concentrates(PCs) by storage, irradiation, and photochemical treatment. Transfusion 1997;37:92s.
25. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999;39:239-48.
26. Roback JD, Hossain MS, Lezhava L. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host-disease following bone marrow transplantation. J Immunol 2003;171:6023-31.
27. Castro G, Merkel PA, Giclas HE, et al. Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease. Transfusion 2018;58:1506-15.
28. Sharma RR, Marwaha N. Leukoreduced blood components: advantages and strategies for its implementation in developing countries. Asian J Transfus Sci 2010;4:3-8.
29. Liu HW, Yuen KY, Cheng TS, et al. Reduction of platelet transfusion- associated sepsis by short-term bacterial culture. Vox Sang 1999;77:1-5.
30. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
31. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75.
32. Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011;153:393-401.
33. Ishida A, Handa M, Wakui M, et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation-a prospective analysis. Transfusion 1998;38:839-47.
34. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348-60.
35. Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333-9.
36. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and pre-storage WBC-reduced platelets. Transfusion 2002;42:556-66.
37. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-603.
38. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003;101:4195-200.
39. Mainou M, Alahdab F, Tobian AA, et al. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. Transfusion 2016;56Pt 2:1569-80.
40. Pelszynski MM, Moroff G, Luban NLC, et al. Effect of gamma irradiation on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion associated graft vs. host disease. Blood 1994;83:1683-9.
41. Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007;370:427-38.
42. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx™ technology. Semin Hematol 2001;38(4 Suppl 11):27-33.
43. Amsler L, Jutzi M. Haemovigilance Annual Report 2015. Bern, Switzerland: Swissmedic; 2016.
44. Fiebig E, Hirschkorn DF, Maino VC, et al. Assessment of donor T-cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma irradiation, and photochemical treatment. Transfusion 2000;40:761-70.
45. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
46. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004;33:1-7.
47. Amato M, Schennach H, Astl M, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang 2016;112:47-55.
48. Schmidt M, Hourfar MK, Sireis W, et al. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Transfusion 2015;55:2104-12.
49. Wagner SJ, Benjamin RJ, Hapip CA, et al. Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation. Vox Sang 2016;111:226-34.